<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349296</url>
  </required_header>
  <id_info>
    <org_study_id>BARIS</org_study_id>
    <nct_id>NCT01349296</nct_id>
  </id_info>
  <brief_title>BIBF 1120 and RAD001 in Solid Tumors - Phase I</brief_title>
  <acronym>BARIS</acronym>
  <official_title>BARIS - BIBF1120 and RAD001 in Solid Tumors. A Phase I Trial to Evaluate the Safety and Tolerability of Combined BIBF 1120 and RAD001 in Solid Tumors and to Determine the Maximum Tolerated Dose (MTD) of the Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIBF1120 and RAD001 in solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in
      solid tumors and to determine the maximum tolerated dose (MTD) of the combination
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of RAD001 in combination with BIBF 1120 (150mg bid or 200mg bid) (endpoint: dose-limiting toxicities)</measure>
    <time_frame>Every visit</time_frame>
    <description>Documentation an estimation of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the tolerability of BIBF1120 and RAD001 in combination (endpoints: assessment of adverse events (AEs) according to CTC-AE V4.0)</measure>
    <time_frame>Every visit during the study</time_frame>
    <description>Documentation an estimation of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical efficacy of the combination descriptively (endpoints: RR, progression free survival (PFS), overall survival (OS))</measure>
    <time_frame>Baseline and every six weeks during the study, after study every 6 months</time_frame>
    <description>CT will be done for evaluation of RR and PFS on day 57 and then every 6 weeks until progression.
For overall survival a telephone call every six months after study is continuation will be done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze individual BIBF1120 pharmacokinetic (PK) parameters at steady-state (ss) of monotherapy and PK parameters of both BIBF1120 and RAD001 at ss of combination</measure>
    <time_frame>day 14, day 29</time_frame>
    <description>Blood collection for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in tumor vasculature a) early under BIBF1120 monotherapy, b) at ss of BIBF1120 monotherapy and c) at ss of combination therapy using dynamic contrast-enhanced MRI (DCE-MRI) (endpoints: IAUC, Ktrans, Kep, Ve)</measure>
    <time_frame>baseline, day 3, day 14, day 29</time_frame>
    <description>DCE MRI will be done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the clinical outcome with FGFR1-amplification status (endpoints: see above for clinical parameters)</measure>
    <time_frame>Screening</time_frame>
    <description>Documentation of histology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>BIBF 1120 + RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus + BIBF 1120</intervention_name>
    <description>Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d</description>
    <arm_group_label>BIBF 1120 + RAD001</arm_group_label>
    <other_name>Everolimus, RAD001, Afinitor, BIBF 1120</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven solid tumor disease after failure of standard
             therapy regimen(s)

          2. Age &gt; 18 years.

          3. ECOG performance status 0 to 1.

          4. Life expectancy of at least 12 weeks.

          5. Subjects with at least one measurable (CT or MRI) lesion.

          6. Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements conducted within 7 days prior to screening:

               -  Hemoglobin &gt; 9.0 g/dl

               -  Absolute neutrophil count (ANC) &gt;1,500/mm3

               -  Platelet count ³ 100,000/μl

               -  Total bilirubin within normal limits

               -  ALT and AST &lt; 1.5 x upper limit of normal ( or &lt; 2.5 x upper limit of normal in
                  patients with liver involvement)

               -  PT-INR/PTT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically
                  anticoagulated with an agent such as coumadin or heparin will be allowed to
                  participate provided that no prior evidence of underlying abnormality in these
                  parameters exists.]

               -  Serum creatinine &lt; 1.5 x upper limit of normal or creatinine clearance (CrCl) ≥
                  50 ml/min calculated by either Cockcroft-Gault or by 24 hours urine collection

          7. More than 14 days since previous chemotherapy, radiotherapy and surgery

          8. Negative urine or serum HCG in women of childbearing potential

          9. Signed and dated informed consent before the start of specific protocol procedures

        Exclusion Criteria:

          1. Limited number of prior lines of treatment (including surgery and radiotherapy, if
             part of the standard therapy of the respective tumor entity)

          2. Prior treatment with BIBF 1120 or any other VEGFR inhibitor (bevacizumab is allowed)

          3. Prior treatment with RAD001 or any other mTOR inhibitor

          4. Known hypersensitivity to the trial drugs, to their excipients or to contrast media

          5. Chemo-, hormono-, radio-(except for brain and extremities) or immunotherapy or therapy
             with monoclonal antibodies or small tyrosine kinase inhibitors within the past 2 weeks
             prior to treatment with the trial drugs

          6. Persistence of clinically relevant therapy related toxicity from previous chemo and/or
             radiotherapy

          7. Active brain metastases (e.g. stable for &lt;4 weeks, no adequate previous treatment with
             radiotherapy, symptomatic, requiring treatment with anticonvulsants; dexamethasone
             therapy will be allowed if administered as stable dose for at least one month before
             trial drug administration) or leptomeningeal metastases (documented by lumbar
             puncture)

          8. History of cardiac disease: congestive heart failure &gt;NYHA class 2; active coronary
             artery disease (CAD), (MI more than 6 mo prior to study entry is allowed); cardiac
             arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted)
             or uncontrolled hypertension

          9. Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of BIBF1120 or RAD001 (e.g. ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
             resection)

         10. History of HIV infection or previously seropositive for the virus

         11. History of Hepatitis B or/and C or previously seropositive for the Hepatitis B or/and
             C virus

         12. Radiographic evidence of cavitary or necrotic tumors

         13. Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of
             major blood vessels

         14. Treatment with other investigational drugs or treatment in another clinical trial
             within the past 30 days before start of therapy or concomitantly with the trial

         15. Patients with seizure disorder requiring enzyme-inducing antiepileptics

         16. Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed
             for maintenance of an indwelling intravenous devise) or antiplatelet therapy (except
             for low-dose therapy with acetylsalicylic acid ≤325mg per day)

         17. Major injuries within the past 10 days prior to start of study treatment with
             incomplete wound healing and/or planned surgery during the on-treatment study period

         18. Evidence or history of bleeding diasthesis or thrombosis, and known inherited
             predisposition to bleeding or thrombosis

         19. Proteinuria CTC AE grade 2 or greater

         20. Active serious infections

         21. Patients undergoing renal dialysis

         22. Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively
             treated &gt; 3 years prior to study entry

         23. Serious illness or concomitant non-oncological disease such as neurologic,
             psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or
             laboratory abnormality that may increase the risk associated with study participation
             or study drug administration and in the judgment of the investigator would make the
             patient inappropriate for entry into the study

         24. Patients who are sexually active and unwilling to use a medically acceptable method of
             contraception (e.g. such as implants, injectables, combined oral contraceptives, some
             intrauterine devices or vasectomized partner for participating females, condoms for
             participating males) during the trial and for at least three months after end of
             active therapy

         25. Pregnancy or breast feeding

         26. Psychological, familial, sociological or geographical factors potentially hampering
             compliance with the study protocol and follow-up schedule

         27. Active alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Wolf, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lung Cancer Group Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Juergen Wolf</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

